Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07227467

Prospective Assessments Following Immediate Lymphatic Reconstruction

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University of Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema.(Chang et al. 2020) It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. To our knowledge, there is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention.

Conditions

Interventions

TypeNameDescription
OTHERpatients who are candidates for immediate lymphatic reconstructionpotential candidates for ILR based on possible nodal involvement assessed preoperatively.

Timeline

Start date
2025-12-01
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2025-11-12
Last updated
2025-12-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07227467. Inclusion in this directory is not an endorsement.